A Decision Support Tool to Identify Patients With Ulcerative Most Likely to Benefit from Vedolizumab vs Adalimumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Inflammatory Bowel Diseases
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab
Inflamm. Bowel Dis. 2022 Oct 03;28(10)1555-1564, PS Dulai, ECL Wong, W Reinisch, JF Colombel, JK Marshall, N NarulaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.